Key facts
- Inotrem’s last known valuation is $89.3M (Sep 2021).
- It has raised $135.9M; the latest was Later Stage VC ($9.0M) in Jun 2025.
- Notable investors include Bpifrance, La French Tech, Sofinnova Partners, Morningside Group, The Invus Group — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Inotrem
- ·The full record, as it builds
Funding rounds
No funding rounds for Inotrem are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inotrem
Developer of novel therapeutics designed to treat inflammatory diseases. The company's therapeutics focus on targeted immunotherapy for acute and chronic inflammatory syndromes and have strong expertise in the biology of the triggering receptor, enabling healthcare professionals to focus on critical care and treat patients with acute and chronic inflammatory conditions.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2013
- Employees
- 30
- Website
- inotrem.com/
- Ownership
- Privately Held (backing)
Inotrem doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inotrem shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inotrem in its N-PORT filings yet. We sweep new filings monthly.